MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The role of LRRK2 in regulating microglial activity in Parkinson’s disease

S. Brooker, A. Thomas, D. Krainc (Chicago, USA)

Meeting: 2024 International Congress

Abstract Number: 925

Keywords: Leucine-rich repeat kinase 2(LRRK2), Microglia, Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To investigate the effects of pathogenic LRRK2 mutations on lysosomal function and phagocytic activity of microglia.

Background: The LRRK2 G2019S mutation is one of the most common genetic causes of  Parkinson’s disease (PD). Pathogenic mutations in LRRK2 have been shown to negatively impact lysosomal function in dopaminergic neurons, but there is emerging evidence that deleterious effects of LRRK2 mutations on immune cell function may additionally play a role in PD pathogenesis. LRRK2 is highly expressed in both microglia and peripheral macrophages. Furthermore, analysis of LRRK2 variants associated with PD has demonstrated that these variants are associated with microglia-specific changes in LRRK2 expression. Further work is needed to define how LRRK2 mutations may result in loss of normal microglial functions or the development of toxic microglial phenotypes in PD.

Method: Induced pluripotent stem cells (iPSCs) were generated from fibroblasts obtained from PD patients with LRRK2 G2019S mutations. Isogenic control iPSCs were produced by using CRISPR/Cas9 technology to correct the G2019S point mutation. These iPSCs were differentiated into microglia and the effects of the LRRK2 G2019S mutation on microglial phenotypes was examined in vitro. Live cell confocal imaging was used to measure microglial phagocytic activity as well as lysosomal protease activity.

Results: iPSC-derived microglia (iMGs) generated from PD patients harboring the LRRK2 G2019S mutation displayed changes in lysosomal morphology as well as differences in expression of lysosomal proteins compared to isogenic control iMGs. In addition, LRRK2 G2019S iMGs had reduced lysosomal protease activity. LRRK2 G2019S microglia furthermore displayed a time-dependent reduction in phagocytic delivery of multiple substrates to the lysosome, including myelin fragments and E.coli.

Conclusion: Human microglia harboring the pathogenic LRRK2 G2019S mutation display defects in lysosomal function accompanied by impaired phagocytosis of multiple substrates. Therefore, microglial lysosomal dysfunction is a potential non-cell autonomous mechanisms by which LRRK2 mutations could contribute to neurodegeneration.

To cite this abstract in AMA style:

S. Brooker, A. Thomas, D. Krainc. The role of LRRK2 in regulating microglial activity in Parkinson’s disease [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/the-role-of-lrrk2-in-regulating-microglial-activity-in-parkinsons-disease/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-role-of-lrrk2-in-regulating-microglial-activity-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley